OakChart

SILO Pharma Inc

SILOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.84+0.05 (2.91%)
2026-11-11 22:35 CET
Market cap
2.84 USD m
Revenue, TTM
0.05 USD m
Net income, TTM
-4.47 USD m
Free cash flow, TTM
-3.34 USD m
EPS diluted, TTM
-5.34
P/E
-
Compare

Price

SILO against its 20, 50 and 200-day averages
2050200
2.004.006.008.003.0M5.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SILOclose 1.8420-day 1.3150-day 1.58200-day 4.401.8452w low

82.3% under the 52-week high of 10.43 on 20 Apr 2026. 52-week low 1.10 on 13 Oct 2026. Last 15 sessions, 73.3% high to low

Volume 1.54× normal · the line is the 50-bar volume average

Profile

SILO
52-week range, 8% of the way up
1.1010.43

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

Employees3
IPOMay 13, 2014
Beta0.83
ATR, 14d0.15
Rel volume1.54
Short float0.96%
Insider own9.75%
Inst own9.42%

Snapshot

6 groups

Valuation

Index-
Market Cap2.92M
Enterprise Value-2.51M
Income-4.47M
Sales0.05M
Book/sh4.33
Cash/sh3.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPOMay 13, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S58.45
P/B0.43
P/C0.54
P/FCF-
EV/EBITDA-
EV/Sales-50.15
Quick Ratio5.36
Current Ratio5.36
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-5.34
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y33.45% 26.52%
Sales past 3/5Y0.00% -
EPS Y/Y TTM65.23%
Sales Y/Y TTM-25.00%
EPS Q/Q73.65%
Sales Q/Q-100.00%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own9.75%
Insider Trans0.00%
Inst Own9.42%
Inst Trans0.89%
ROA-70.96%
ROE-91.23%
ROIC-91.52%
Gross Margin-1329.43%
Oper. Margin-8250.46%
Profit Margin-8269.53%
SMA2040.39%
SMA5016.25%
SMA200-58.14%
Trades-

Technical

Shs Outstand1.59M
Shs Float1.43M
Short Float0.96%
Short Ratio0.14
Short Interest0.01M
52W High10.43 -82.33%
52W Low1.10 67.46%
Volatility15.72% 9.42%
ATR (14)0.15
RSI (14)69.63
Beta0.83
Rel Volume1.54
Avg Volume96.07K
Volume147,890

Performance

Perf Week38.50%
Perf Month50.99%
Perf Quarter-42.79%
Perf Half Y-68.54%
Perf YTD-63.88%
Perf Year-73.60%
Perf 3Y-90.97%
Perf 5Y-98.77%
Perf 10Y-99.55%
Recom1.00
Target Price150.00
Prev Close1.79
Price1.84
Change %2.91%

Peers

Mkt cap
TickerCompanyMkt cap
CMNDClearmind Medicine Inc2.51M
ENVBEnveric Biosciences Inc6.67M
NEUPNeuphoria Therapeutics Inc14.66M
PBMPsyence Biomedical Ltd12.13M
VTGNVistagen Therapeutics Inc8.34M
TNXPTonix Pharmaceuticals Holding Corp75.20M
OGENOragenics Inc1.54M
SPRCSciSparc Ltd0.82M
ADXNAddex Therapeutics Ltd ADR3.02M
DRUGBright Minds Biosciences Inc231.32M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Weisblum EricChief Executive OfficerDec 15 '25Buy0.415,0002,075216,932Dec 16 06:34 PM
Weisblum EricChief Executive OfficerNov 20 '25Buy0.371,000370210,932Nov 21 06:35 PM
Weisblum EricChief Executive OfficerNov 21 '25Buy0.361,000365211,932Nov 21 06:35 PM
Weisblum EricChief Executive OfficerNov 18 '25Buy0.407,5003,025205,432Nov 20 04:00 PM
Weisblum EricChief Executive OfficerNov 19 '25Buy0.414,5001,823209,932Nov 20 04:00 PM

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility (GlobeNewswire) -6.21%
  • Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio (GlobeNewswire) +6.98%
  • Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum (GlobeNewswire) -5.70%
  • Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment (GlobeNewswire) -6.84%
  • Silo Pharma Granted European Patent Covering Novel PTSD Therapy (GlobeNewswire)
  • Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform (GlobeNewswire)
  • Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program (GlobeNewswire)
  • Silo Pharmas QwikAgents Joins AMD AI Developer Program to Advance AI Agent Platform (InvestorsHub)
  • Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform (GlobeNewswire)
  • Silo Pharma Shares Slide After Announcing Up to $11.7 Million Private Placement (SILO) (InvestorsHub) -26.26%
  • CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall (Investing.com)
  • Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
  • Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program (GlobeNewswire) -9.00%
  • Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q12025-05-09-3.450--0.02--
2023Q22023-08-30-4.800-4.800-4.8180.020.021
2023Q12023-08-25-4.350--4.3040.02--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-15.300-15.300-18.0240.070.07
2024FY-17.850--0.07-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2023Q3S2023-11-271000.020.020.02
2023Q3S2023-11-261000.020.020.02
2023Q3S2023-11-251000.020.020.02
2023Q3S2023-11-221000.020.020.02
2023Q3S2023-11-211000.020.020.02
2023Q3S2023-11-201000.020.020.02
2023Q3S2023-11-191000.020.020.02
2023Q3S2023-11-181000.020.020.02
2023Q3S2023-11-151000.020.020.02
2023Q3S2023-11-141000.020.020.02
2023Q3S2023-11-131000.020.020.02
2023Q3S2023-11-121000.020.020.02
2023Q3S2023-11-111000.020.020.02
2023Q3S2023-11-081000.020.020.02

Estimate history

EPS, annual7.5-14.805-32.385-35.32519.53-25.666-18.024-17.904-7.565-5.3382
Period201720182019202020212022202320242025TTM
EPS, quarterly-4.579-3.239-5.789-3.45-2.877-1.785-0.993-1.802-0.758
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual-0.06500.04100.0710.0720.0720.0720.0720.05
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0180.0180.0180.0180.0180.0180.0180.0180
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0670.0310.0310.1140.1320.2110.1940.2990.8881.129
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.2480.2990.2990.2990.5770.6970.8881.0841.129
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.050.070.070.070.070.070.000.040.00
Cost of Goods Sold Incl. D&A0.770.890.920.880.580.400.000.350.02
Gross Profit-0.72-0.81-0.85-0.81-0.51-0.330.00-0.31-0.02
Selling, General and Administrative Excl. Other3.743.473.862.962.992.312.200.590.48
Research and Development2.162.162.370.851.290.690.030.06-
Other Operating Expense0.000.000.000.090.130.110.000.000.00
Operating Income-4.46-4.28-4.71-3.86-3.63-2.74-2.20-0.90-0.49
Interest Expense0.040.040.010.000.000.000.270.06-
Unusual Expense0.130.110.000.170.33-0.270.210.200.38
Net Income Before Taxes-4.47-4.23-4.39-3.63-3.914.18-2.67-1.01-0.97
Income Taxes0.000.000.000.000.000.020.000.000.00
Consolidated Net Income-4.47-4.23-4.39-3.63-3.914.16-2.67-1.01-0.97
Net Income From Continuing Operations-4.47-4.23-4.39-3.63-3.914.16-2.67-1.01-0.97
Net Income-4.47-4.23-4.39-3.70-3.912.50-3.11-1.01-0.97
EPS (Recurring)-3.99-7.43-17.90-17.45-24.1418.07-33.68-27.92-10.77
EPS (Basic, Before Extraordinaries)-5.34-7.57-17.90-18.02-25.6719.75-35.33-32.38-14.80
EPS (Diluted)-5.34-7.57-17.90-18.02-25.6719.53-35.33-32.38-14.80
EBITDA-4.45-4.27-4.70-3.86-3.63-2.74-2.20-0.90-0.48
Non-Operating Income (Expense)0.160.200.320.400.056.660.010.15-0.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.120.000.010.000.06---
Price To Earnings Ratio-----6.85---
Price To Sales Ratio126.1539.5345.4361.51106.45191.81684.00202.47-
Gross Margin-1,329.43-1,128.89-1,174.30-1,116.97-709.25-461.47--755.27-
Operating Margin-8,250.46-5,936.95-6,526.44-5,347.41-5,031.28-3,850.95--2,220.82-
Net Margin-8,269.53-5,863.50-6,092.59-5,132.57-5,420.863,505.54--2,497.71-
Shares Outstanding1.130.890.300.190.210.130.110.030.03
Market Capitalization2.842.843.994.4810.5514.0636.138.2652.08

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.020.020.020.020.020.020.02
Cost of Goods Sold Incl. D&A0.000.270.250.250.200.180.400.17
Gross Profit-0.00-0.25-0.24-0.23-0.18-0.16-0.38-0.16
Selling, General and Administrative Excl. Other0.931.350.550.921.070.931.500.83
Research and Development0.301.010.310.540.720.591.080.52
Other Operating Expense0.000.000.000.000.000.000.000.02
Operating Income-0.93-1.59-0.79-1.15-1.25-1.09-1.88-1.01
Interest Expense0.000.000.030.000.000.000.000.00
Unusual Expense-0.060.090.110.000.000.000.000.00
Net Income Before Taxes-0.83-1.65-0.88-1.11-1.20-1.03-1.73-0.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-0.83-1.65-0.88-1.11-1.20-1.03-1.73-0.93
Net Income From Continuing Operations-0.83-1.65-0.88-1.11-1.20-1.03-1.73-0.93
Net Income-0.83-1.65-0.88-1.11-1.20-1.03-1.73-0.93
EPS (Recurring)-0.80-1.74-0.91-1.78-2.88-3.45-5.79-3.24
EPS (Basic, Before Extraordinaries)-0.76-1.80-0.99-1.78-2.88-3.45-5.79-3.24
EPS (Diluted)-0.76-1.80-0.99-1.78-2.88-3.45-5.79-3.24
EBITDA-0.93-1.59-0.78-1.15-1.25-1.09-1.87-1.01
Non-Operating Income (Expense)0.040.040.040.040.050.060.080.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.040.060.050.050.02--0.00
Price To Sales Ratio126.1568.3962.8089.3054.8772.7755.3565.63
Gross Margin--1,377.08-1,303.76-1,291.16-1,005.34-915.32-2,118.26-866.92
Operating Margin--8,846.44-4,363.28-6,388.16-6,926.77-6,069.68-10,414.16-5,603.63
Net Margin--9,137.45-4,890.33-6,160.54-6,681.24-5,721.94-9,600.69-5,152.92
Shares Outstanding1.131.080.890.700.580.300.300.30
Market Capitalization2.845.854.537.225.455.253.994.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments6.867.087.6711.3710.261.130.120.560.29
Short Term Receivables0.000.000.000.070.000.020.200.000.00
Inventories0.000.000.000.000.000.000.160.030.00
Other Current Assets0.530.030.020.140.150.270.020.03-
Total Current Assets7.397.117.6811.5710.401.430.490.630.32
Net Property, Plant & Equipment0.000.000.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.001.32
Long-Term Note Receivable---0.000.060.000.000.20-
Intangible Assets0.220.240.000.000.000.000.000.030.00
Other Assets0.000.060.060.070.030.000.000.000.03
Total Assets7.617.417.7511.6410.491.430.490.861.64
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.010.060.020.00
Accounts Payable0.581.580.700.360.420.130.050.03-
Other Current Liabilities0.070.070.070.070.070.00-0.00-0.000.04
Total Current Liabilities0.651.660.780.440.490.140.120.050.04
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.650.720.790.870.940.000.000.000.00
Total Liabilities1.302.381.571.301.430.150.120.050.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.400.400.40
Common Equity6.315.036.1810.349.061.28-0.020.411.20
Total Shareholders Equity6.315.036.1810.349.061.280.380.811.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6.315.036.1810.349.061.280.380.811.60
Total Liabilities & Stockholders Equity7.617.417.7511.6410.491.430.490.861.64
Book Value Per Share7.1016.8431.8849.1068.9111.28-0.7313.0518.02
Tangible Book Value Per Share6.8616.0331.8849.1068.9111.28-0.7312.1118.02
Full-Time Employees3333221--
Price to Book Ratio0.410.790.600.891.5528.21-360.8951.7510.06
Return on Assets-56.31-57.96-37.46-35.3169.77-277.66-150.20-77.6624.25
Return on Equity-74.56-78.37-43.97-40.2880.39-321.66-171.09-80.4425.02
Return on Invested Capital-67.05-87.26-59.91-37.8043.06-236.39-268.70-120.0722.24
Quick Ratio11.364.299.9026.5221.2310.072.8912.498.38
Current Ratio11.364.299.9026.5221.2310.074.2313.058.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-4.47-4.23-4.39-3.70-3.913.90-3.04-1.01-0.97
Depreciation0.010.010.01----0.000.02
Other Funds (Non Cash)1.650.740.000.180.49-6.891.970.301.24
Funds from Operations-2.81-3.48-4.39-3.52-3.42-2.98-1.07-0.710.29
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.53-1.180.550.30-0.080.70-0.09-0.08-0.02
Cash from Operating Activities-3.34-4.66-3.83-3.22-3.50-2.28-1.16-0.790.27
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.121.220.97-4.150.077.020.000.190.00
Purchase of Investments-0.13-0.10-0.18-4.150.000.000.00-0.010.00
Sale Or Maturity of Investments0.251.321.150.000.077.020.000.190.00
Other Uses-0.57-0.570.000.000.000.000.000.00-0.25
Other Sources0.000.000.000.000.020.170.040.000.00
Cash from Investing Activities-0.460.640.97-4.150.097.190.040.19-0.25
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.744.863.24-0.474.943.792.120.110.02
Repurchase of Common Pref Stock0.000.00-0.17-0.470.000.000.000.00-0.00
Sale of Common Pref Stock2.744.863.410.004.943.792.120.110.02
Proceedsfrom Stock Options-0.030.000.000.004.943.792.120.110.02
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.020.27-0.00
Change in Long Term Debt0.000.000.000.000.000.000.020.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.020.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities2.744.863.24-0.474.943.792.130.380.02
Net Change in Cash-1.060.840.38-7.841.538.711.02-0.220.04
Free Cash Flow-3.34-4.66-3.83-3.22-3.50-2.28-1.16-0.790.27
Preferred Dividends (Cash Flow)-0.000.000.000.00--0.000.00
Price to Free Cash Flow--------192.73
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.436.276.865.946.265.45
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.280.530.530.230.110.15
Total Current Assets5.716.807.396.166.375.60
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.210.210.220.220.220.24
Other Assets0.030.000.000.000.060.06
Total Assets5.957.027.616.386.655.90
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.360.630.580.640.981.11
Other Current Liabilities0.700.070.070.070.070.07
Total Current Liabilities1.070.700.650.711.051.19
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.630.650.670.690.70
Total Liabilities1.071.341.301.381.741.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.895.686.315.014.924.01
Total Shareholders Equity4.895.686.315.014.924.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.895.686.315.014.924.01
Total Liabilities & Stockholders Equity5.957.027.616.386.655.90
Book Value Per Share4.335.247.107.188.5313.42
Tangible Book Value Per Share4.145.046.866.878.1412.62
Full-Time Employees--3---
Price to Book Ratio0.411.030.721.441.111.31
Return on Assets-70.96-74.99-56.31-67.91-66.64-72.00
Return on Equity-91.23-99.94-74.56-86.11-90.03-99.38
Return on Invested Capital-17.04-28.99-13.98-22.17-24.49-25.71
Quick Ratio5.369.6511.368.706.074.73
Current Ratio5.369.6511.368.706.074.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.83-1.65-0.88-1.11-1.20-1.03
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)0.040.880.160.570.02-0.00
Funds from Operations-0.79-0.76-0.72-0.54-1.19-1.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.01-0.06-0.06-0.42-0.10-0.61
Cash from Operating Activities-0.78-0.82-0.78-0.96-1.29-1.64
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.18-0.020.05-0.100.390.87
Purchase of Investments-0.02-0.070.05-0.10-0.02-0.03
Sale Or Maturity of Investments0.200.050.000.000.410.91
Other Uses0.000.00-0.570.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.18-0.02-0.52-0.100.390.87
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.030.002.130.632.090.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.030.002.130.632.090.00
Proceedsfrom Stock Options-0.030.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.030.002.130.632.090.00
Net Change in Cash-0.63-0.850.83-0.421.20-0.77
Free Cash Flow-0.78-0.82-0.78-0.96-1.29-1.64

Revenue breakdown

Pharmaceutical Preparations2024: 72.10K 2025: 72.10K
United States2024: 72.10K 2025: 72.10K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.96%0.0M1.4M95.16K
2026-10-151.54%0.0M1.4M97.16K
2026-09-302.44%0.0M1.4M191.64K
2026-09-152.03%0.0M1.4M194.36K
2026-08-312.32%0.0M1.4M194.57K
2026-08-145.97%0.1M1.4M163.63K
2026-07-3111.72%0.1M1.1M153.12K
2026-07-1513.97%0.2M1.1M211.43K
2026-06-301.56%0.0M1.1M289.14K
2026-06-151.57%0.0M1.1M273.69K
2026-05-292.01%0.0M1.1M273.25K
2026-05-154.56%0.0M1.1M324.35K
2026-04-304.83%0.1M1.1M327.15K
2026-04-153.27%0.0M1.1M272.35K
2026-03-312.37%0.0M0.9M63.73K
2026-03-132.44%0.0M0.9M63.96K
2026-02-274.50%0.0M0.9M61.59K
2026-02-133.75%0.0M0.9M9.14K
2026-01-304.38%0.0M0.8M9.75K
2026-01-154.59%0.0M0.8M18.09K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-068-KCurrent report2026-11-05SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-028-KCurrent report2026-10-01SEC
2026-08-198-KCurrent report2026-08-18SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-06EFFECTEffectiveness filing by commission orderSEC
2026-08-06424B3SEC
2026-07-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-24S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-14DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-138-KCurrent report2026-07-09SEC
2026-07-08SCHEDULE 13GSEC
2026-06-30ARSAnnual report to security holders. 2025-12-31SEC
2026-06-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-06-038-KCurrent report2026-06-01SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-16424B3SEC
2026-04-15EFFECTEffectiveness filing by commission orderSEC
2026-04-14424B3SEC
2026-04-14POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-13EFFECTEffectiveness filing by commission orderSEC
2026-04-10POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-028-KCurrent report2026-03-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-122.08K100
2025-115.58K400

Institutional holders

Manager% owned
AdvisorShares Investments LLC6.52%
CITADEL ADVISORS LLC1.49%
VANGUARD CAPITAL MANAGEMENT LLC1.06%
GEODE CAPITAL MANAGEMENT, LLC0.71%
FNY Investment Advisers, LLC0.31%
VANGUARD FIDUCIARY TRUST CO0.08%
UBS Group AG0.02%
Tower Research Capital LLC0.02%
IFP Advisors, Inc0.02%
HARBOUR INVESTMENTS, INC.0.00%

Funds

Fund% owned
Avantis Emerging Markets ex-China Equity ETF17.38%
Avantis Emerging Markets Equity Fund15.50%
AdvisorShares Psychedelics ETF6.70%
Avantis Emerging Markets Value ETF5.56%
VANGUARD EXTENDED MARKET INDEX FUND1.06%
Avantis Emerging Markets Equity ETF0.60%
Fidelity Extended Market Index Fund0.54%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.02%

OakChart. SILO. Cached 15 minutes.

Some panels did not load: ratings.